PERKINELMER INC Stock Price, News & Analysis

PerkinElmer (NYSE: PKI), a leading global innovator for a healthier world, will present at the 2022 Stifel Healthcare Conference on November 16, 2022, at 9:10 a.m. ET in New York, NY. Max Krakowiak, the CFO, will discuss the company's strategic priorities during a fireside chat. Interested attendees can register here. A live audio webcast will be available on the investor relations website, with a replay accessible for 90 days.

PerkinElmer reported third quarter 2022 results, revealing a GAAP EPS from continuing operations of $0.55, down from $0.94 a year ago. Revenue decreased 17% year-over-year to $712 million, with pro forma revenue at $1.03 billion, reflecting a 12% organic growth excluding COVID-related impacts. The company anticipates fourth quarter revenue of approximately $0.73 billion and full year revenue of $3.30 billion. Adjusted EPS for the quarter was $1.51, compared to $2.31 last year. Challenges persist in the Diagnostics segment, which saw a 39% decline in revenue.

Epic Sciences has appointed William J. Kullback as the new Chief Financial Officer (CFO), succeeding Joel S. Smith, who retains other executive roles. Kullback brings 27 years of experience, previously leading BioLegend's $5.25 billion acquisition by PerkinElmer (PKI). The company anticipates significant growth from the recent launch of DefineMBC™, aimed at enhancing breast cancer diagnostics, which is expected to boost operations and revenue in 2023. Kullback's expertise will be vital for scaling the organization to meet increasing demand.

The Board of Directors of PerkinElmer (NYSE: PKI) has announced a regular quarterly dividend of $0.07 per share. This dividend will be payable on February 10, 2023, to all shareholders registered by the close of business on January 20, 2023. In 2021, PerkinElmer reported revenue of approximately $5 billion and employs over 16,000 individuals worldwide. The company operates in 190 countries and is part of the S&P 500 Index.

PerkinElmer, Inc. (NYSE: PKI) will release its third quarter 2022 financial results on November 8, 2022. The management will host a webcast at 8:00 a.m. ET to discuss the results. The company anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share to exceed prior guidance. Total revenue is expected to be near the high end of prior guidance, facing headwinds from foreign exchange. The company's revenue in 2021 was approximately $5 billion, serving customers in 190 countries.

PerkinElmer has partnered with Ghana Health Services and the Sickle Cell Foundation to enhance neonatal screening for sickle cell disease (SCD) in Ghana. The goal is to increase screening from 4% to 50% by 2030, with a donation facilitating the capacity to screen an additional 50,000 babies yearly. Their scalable MigeleTM Gel Electrophoresis Systems are designed to support this initiative, enabling reliable and cost-effective screening. PerkinElmer aims to bolster sustainable healthcare solutions and educate communities about early SCD intervention.

PerkinElmer, a leader in life sciences, has launched the Cellaca® PLX Image Cytometry System, a groundbreaking benchtop platform for assessing multiple Critical Quality Attributes (CQAs) of cell samples. This system streamlines workflows by allowing simultaneous detection of various markers and performing rapid assays without the need for complex calibrations. Targeted especially at pharmaceutical research, particularly in CAR-T cell therapy, the Cellaca PLX promises to enhance the analysis of complex cell samples, facilitating compliance with scientific and regulatory standards.

PerkinElmer has announced FDA approval for the T-Cell Select™ reagent kit to automate the T-SPOT.TB test, enhancing lab workflow efficiency. This kit facilitates a standardized blood sample process, minimizing complex practices and allowing for room temperature storage for up to 54 hours. It is notable as the first automated IGRA TB test without regulatory warnings for immunocompromised patients. The product is set to expand access to superior latent TB testing across laboratories in the U.S. and beyond.